In summary, combining specific STAT3 inhibition with the well tolerated and approved drug metformin may represent a promising new strategy for the treatment of high-grade glioma, but pharmacokinetic aspects, such as drug delivery to the brain and clinically achievable drug doses still need to be clarified. This evidence concerns the gene STAT3 and glioma.